STOCK COMPARISON
Seegene vs Vertex Pharmaceuticals: Fair Value & Quality
Both stocks run through our valuation models. Here is how Seegene (096530) and Vertex Pharmaceuticals (VRTX) compare, as of Aug 10, 2026.
As of Aug 10, 2026, Fair Value Calculator sees Seegene as the less overvalued of the two: Seegene trades at KRW 28,900 versus a fair value of KRW 18,011 (-38%), while Vertex Pharmaceuticals trades at $496 versus $279 (-44%).
Seegene
096530.KQ · KRW · Health Care
-38%
upside to fair value
overvalued
PriceKRW 28,900
Fair ValueKRW 18,011
Quality79/100
Vertex Pharmaceuticals
VRTX · USD · Health Care
-44%
upside to fair value
overvalued
Price$496
Fair Value$279
Quality79/100
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
SeegeneVertex Pharmaceuticals
Valuation
—P/E (TTM)28.8×
—P/S (TTM)10.06×
—P/B6.59×
—EV/EBITDA23.8×
—PEG1.72×
4.2%Dividend yield—
KRW 1,200Dividend per share—
Profitability
13%Net margin36%
18%Operating margin38%
6%Return on equity24%
2%Return on assets12%
Growth
11%Revenue growth (YoY)8%
-17.8%Avg. growth/yr (3Y)10.6%
-15.9%Avg. growth/yr (5Y)14.2%
Balance & size
—Debt / equity0.03×
$911MMarket cap$123B
weakGrowth qualityhealthy
Vertex Pharmaceuticals leads: 1 to 6 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
Seegeneof which business quality 76 · market factors 49
Vertex Pharmaceuticalsof which business quality 77 · market factors 65
ProfitabilityMargins and returns on capital today
36
72
Quality GrowthAre margins and returns improving?
84
65
CashflowEarnings quality: real cash, not paper profit
89
79
Fin. StrengthBalance sheet, leverage, solvency risk
80
92
InvestmentDisciplined investing over empire-building
88
58
Low VolatilityCalm price path (market factor)
47
86
MomentumPrice trend over the last 3–12 months (market factor)
51
54
52W MomentumDistance to the 52-week high (market factor)
49
59
Net IssuanceBuybacks instead of dilution
97
82
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Seegene
DCF ModelsKRW 60,142
Earnings-BasedKRW 35,726
MultiplesKRW 18,011
Asset-BasedKRW 14,932
Growth DCFKRW 61,028
Economic ProfitKRW 13,427
Growth EarningsKRW 47,765
9 of 24 models see the stock below the current price.
Vertex Pharmaceuticals
DCF Models$453
Earnings-Based$516
Dividend Discount$7.07
Multiples$278
Asset-Based$49.27
Growth DCF$348
Economic Profit$254
Growth Earnings$692
18 of 26 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Seegene
Bear KRW 17,357Fair Value KRW 18,011Bull KRW 22,514
KRW 28,900 = current price (white tick)
Vertex Pharmaceuticals
Bear $210Fair Value $279Bull $900
$496 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Seegene · Health Care
Quality score79 · Top 25%
Fair value upside-38% · below median
Vertex Pharmaceuticals · Health Care
Quality score79 · Top 25%
Fair value upside-44% · below median
Bottom line
As of Aug 10, 2026, Fair Value Calculator sees Seegene as the less overvalued of the two: Seegene trades at KRW 28,900 versus a fair value of KRW 18,011 (-38%), while Vertex Pharmaceuticals trades at $496 versus $279 (-44%).
Seegene has the higher quality score (79/100).
See the full analysis →
More comparisons
Popular match-ups from the same sectors, all with fair value and quality score.
Free · Top-25 report
See the undervalued quality stocks every month
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
